Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 6Unituxin

PharmaCompass

01

Brand Name : Unituxin

Dinutuximab

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Unituxin

arrow
BIO Asia-Taiwan
Not Confirmed

Dinutuximab

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 114

2018 Revenue in Millions : 85

Growth (%) : 34

blank

02

Brand Name : Unituxin

Dinutuximab

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Unituxin

arrow
BIO Asia-Taiwan
Not Confirmed

Dinutuximab

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 123

2019 Revenue in Millions : 114

Growth (%) : 8

blank

03

Brand Name : Unituxin

Dinutuximab

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Unituxin

arrow
BIO Asia-Taiwan
Not Confirmed

Dinutuximab

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 202

2020 Revenue in Millions : 123

Growth (%) : 65

blank

04

Brand Name : Unituxin

Dinutuximab

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Unituxin

arrow
BIO Asia-Taiwan
Not Confirmed

Dinutuximab

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 183

2021 Revenue in Millions : 202

Growth (%) : -10

blank

05

Brand Name : Unituxin

Dinutuximab

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Unituxin

arrow
BIO Asia-Taiwan
Not Confirmed

Dinutuximab

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 199

2022 Revenue in Millions : 183

Growth (%) : 9

blank

06

Brand Name : Unituxin

Dinutuximab

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Unituxin

arrow
BIO Asia-Taiwan
Not Confirmed

Dinutuximab

Main Therapeutic Indication : Oncology

Currency : USD

2024 Revenue in Millions : 239

2023 Revenue in Millions : 199

Growth (%) : 20

blank